Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) EPS (Weighted Average and Diluted) (2020 - 2025)

Avidity Biosciences (RNA) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$1.59 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 96.3% year-over-year to -$1.59, compared with a TTM value of -$4.97 through Dec 2025, down 71.38%, and an annual FY2025 reading of -$4.97, down 71.97% over the prior year.
  • EPS (Weighted Average and Diluted) was -$1.59 for Q4 2025 at Avidity Biosciences, down from -$1.27 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.65 in Q2 2024 and bottomed at -$1.59 in Q4 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.86, with a median of -$0.8 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) increased 28.26% in 2023, then plummeted 96.3% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.84 in 2021, then decreased by 5.95% to -$0.89 in 2022, then increased by 10.11% to -$0.8 in 2023, then fell by 1.25% to -$0.81 in 2024, then tumbled by 96.3% to -$1.59 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for RNA at -$1.59 in Q4 2025, -$1.27 in Q3 2025, and -$1.21 in Q2 2025.